Corvus Pharmaceuticals, Inc. (CRVS) Current Ratio
- Current ratio · latest quarter: Value 16.16×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 16.16× | Current assets / current liabilities. $220.97M ÷ $13.67M ≈ 16.16× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 220.97M USD | Assets, Current |
| Current obligations | 13.67M USD | Liabilities, Current |
| Cash and equivalents | 18.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 196.32M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 6.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 4.05M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $220.97M | $13.67M | $18.91M | $196.32M | $6.00K | (m) | $4.05M | (m) | 16.16× |
| 2026-03-31 | $239.95M | $12.11M | $40.10M | $196.61M | $43.00K | (m) | $4.70M | (m) | 19.81× |
| 2025-12-31 | $58.21M | $9.38M | $4.58M | $52.17M | $37.00K | (m) | $2.49M | (m) | 6.21× |
| 2025-09-30 | $66.94M | $8.07M | $2.87M | (m) | $32.00K | (m) | $1.97M | (m) | 8.29× |
| 2025-06-30 | $75.78M | $8.51M | $14.69M | (m) | $86.00K | (m) | $3.14M | (m) | 8.91× |
| 2025-03-31 | $45.49M | $9.28M | $5.00M | (m) | $79.00K | (m) | $1.31M | (m) | 4.90× |
| 2024-12-31 | $54.41M | $35.40M | $8.74M | $43.22M | $75.00K | (m) | $2.58M | (m) | 1.54× |
| 2024-09-30 | $42.92M | $46.41M | $4.68M | (m) | $70.00K | (m) | $1.87M | (m) | 0.92× |
| 2024-06-30 | $48.26M | $13.34M | $14.84M | (m) | $35.00K | (m) | $1.21M | (m) | 3.62× |
| 2024-03-31 | $22.85M | $6.72M | $7.46M | (m) | $26.00K | (m) | $1.61M | (m) | 3.40× |
| 2023-12-31 | $27.96M | $6.87M | $12.62M | (m) | $26.00K | (m) | $1.52M | (m) | 4.07× |
| 2023-09-30 | $33.09M | $7.30M | $20.11M | (m) | $11.00K | (m) | $1.40M | (m) | 4.53× |
| 2023-06-30 | $37.91M | $7.86M | $7.66M | (m) | (m) | (m) | $2.10M | (m) | 4.82× |
| 2023-03-31 | $35.55M | $8.29M | $9.65M | (m) | (m) | (m) | $1.41M | (m) | 4.29× |
| 2022-12-31 | $43.66M | $10.75M | $13.16M | (m) | $588.00K | (m) | $1.98M | (m) | 4.06× |
| 2022-09-30 | $51.27M | $13.98M | $24.59M | (m) | (m) | (m) | $4.23M | (m) | 3.67× |
| 2022-06-30 | $58.88M | $10.16M | $28.48M | (m) | (m) | (m) | $2.65M | (m) | 5.80× |
| 2022-03-31 | $64.37M | $9.27M | $31.46M | (m) | (m) | (m) | $2.19M | (m) | 6.95× |
| 2021-12-31 | $71.31M | $9.69M | $63.46M | (m) | (m) | (m) | $1.56M | (m) | 7.36× |
| 2021-09-30 | $78.76M | $11.30M | $72.30M | (m) | (m) | (m) | $2.33M | (m) | 6.97× |
| 2021-06-30 | $69.12M | $12.36M | $58.91M | (m) | (m) | (m) | $2.87M | (m) | 5.59× |
| 2021-03-31 | $68.81M | $13.92M | $45.10M | (m) | (m) | (m) | $4.91M | (m) | 4.94× |
| 2020-12-31 | $45.34M | $12.15M | $16.45M | (m) | (m) | (m) | $3.47M | (m) | 3.73× |
| 2020-09-30 | $52.51M | $12.00M | $22.98M | (m) | (m) | (m) | $2.57M | (m) | 4.38× |
| 2020-06-30 | $60.56M | $11.55M | $20.70M | (m) | (m) | (m) | $2.78M | (m) | 5.24× |
| 2020-03-31 | $69.84M | $11.71M | $23.50M | (m) | (m) | (m) | $3.36M | (m) | 5.96× |
| 2019-12-31 | $79.34M | $10.22M | $5.15M | (m) | (m) | (m) | $2.45M | (m) | 7.76× |
| 2019-09-30 | $87.83M | $9.52M | $9.07M | (m) | (m) | (m) | $1.91M | (m) | 9.23× |
| 2019-06-30 | $98.14M | $10.70M | $30.18M | (m) | (m) | (m) | $2.64M | (m) | 9.17× |
| 2019-03-31 | $107.00M | $8.63M | $38.98M | (m) | (m) | (m) | $2.26M | (m) | 12.39× |
| 2018-12-31 | $115.59M | $7.03M | $39.20M | (m) | (m) | (m) | $2.00M | (m) | 16.45× |
| 2018-09-30 | $124.53M | $7.75M | $40.75M | (m) | (m) | (m) | $1.89M | (m) | 16.07× |
| 2018-06-30 | $134.43M | $9.78M | $28.07M | (m) | (m) | (m) | $2.25M | (m) | 13.75× |
| 2018-03-31 | $145.17M | $10.60M | $102.56M | (m) | (m) | (m) | $3.50M | (m) | 13.69× |
| 2017-12-31 | $91.23M | $8.97M | $45.11M | (m) | (m) | (m) | $3.45M | (m) | 10.17× |
| 2017-09-30 | $100.87M | $9.97M | $44.10M | (m) | (m) | (m) | $3.58M | (m) | 10.11× |
| 2017-06-30 | $111.63M | $9.52M | $34.09M | (m) | (m) | (m) | $4.14M | (m) | 11.73× |
| 2017-03-31 | $123.11M | $7.58M | $10.49M | (m) | (m) | (m) | $2.42M | (m) | 16.24× |
| 2016-12-31 | $136.03M | $5.94M | $5.05M | (m) | (m) | (m) | $1.90M | (m) | 22.89× |
| 2016-09-30 | $146.04M | $5.60M | $5.58M | (m) | (m) | (m) | $2.42M | (m) | 26.10× |
| 2016-06-30 | $153.50M | $3.61M | $4.34M | (m) | (m) | (m) | $1.32M | (m) | 42.55× |
| 2016-03-31 | $154.07M | $3.38M | $4.07M | (m) | (m) | (m) | $1.58M | (m) | 45.54× |
| 2015-12-31 | $95.66M | $3.07M | $4.11M | (m) | (m) | (m) | $1.57M | (m) | 31.16× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |